Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

MigraKind 50 mg Film-Coated Tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Sumatriptan succinate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Sumatriptan succinate

Equivalent medicines (same active substance, strength and form)

and 1 more with the same active substance, strength and form

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

MigraKind is used to treat migraine. These tablets contain sumatriptan, which belongs to a group of medicines called triptans (5-HT, receptor agonists). Migraine symptoms may be caused by the temporary swelling of blood vessels in the head due to a temporary imbalance in the body's natural chemicals. The tablets are believed to work on this imbalance and reduce the swelling of these blood vessels. The tablets help to take away the headache and other symptoms of a migraine attack such as feeling sick (nausea) and sensitivity to light and sound. They start to relieve migraine headache about 30 minutes after you take them.

2.

What you need to know before you take it

e MigraKind

Do not take MigraKind:

  • If you're allergic to sumatriptan, or any of the other ingredients of this medicine (listed in section 6)
  • If you have a heart problem such as narrowing of the arteries (Ischaemic heart disease) or chest pains (angina), or have already had a heart attack
  • If you have circulation problems in your legs that cause cramp-like pains when you walk (peripheral vascular disease)
  • If you have had a stroke or a mini-stroke (also called a transient ischaemic attack or TIA)
  • If you have high blood pressure. You may be able to use MigraKind if your high blood pressure is mild and is being treated
  • If you have serious liver disease
  • With other migraine medicines, including those which contain ergotamine, or similar medicine such as methysergide maleate;
  • or any triptan or 5HT1 agonist (such as naratriptan or zolmitriptan)
  • With any of the following anti-depressants:
  • MAOIs (monoamine oxidase inhibitors) or if you have taken an MAOI in the last 2 weeks For children under 18 years of age. If any of these apply to you: Tell your doctor, and don't use MigraKind tablets. Take special care with MigraKind Talk to your doctor or pharmacist before using MigraKind. If you have any extra risk factors
  • If you are a heavy smoker, or using nicotine replacement therapy, and especially
  • If you are a man aged over 40, or
  • you are very overweight

• • • •

you have diabetes you have high cholesterol you have a close relative who developed early heart disease – either your father or brother developed heart disease before the age of 55, or your mother or sister developed heart disease before the age of 65.

If three or more of the points above apply to you, you may be at higher risk of heart disease- see your doctor without taking If you are a woman who has been through the menopause. In very rare cases, people have developed serious heart conditions after using MigraKind, even though they had no signs of heart disease before. If any of the points above applies to you it could mean you have a greater risk of developing heart disease – so:

  • Tell your doctor so that your heart function can be checked before MigraKind. is prescribed for you. If you have a history of fits (seizures) Or if you have other conditions which might make it more likely that you'll have a fit – for example, a head injury or alcoholism:
  • Tell your doctor so that you can be supervised more closely. If you have had high blood pressure MigraKind may not be suitable for you
  • Tell your doctor or pharmacist before using MigraKind, If you have liver or kidney disease If either of these apply to you:
  • Tell your doctor or pharmacist before using MigraKind, If you have an intolerance to some sugars
  • Tell your doctor so that you can be supervised more closely. If you are allergic to antibiotics called sulphonamides If so, you may also be allergic to MigraKind, If you know you are allergic to an antibiotic but you are not sure whether it is a sulphonamide:
  • Tell your doctor or pharmacist before using MigraKind. If you are taking anti-depressants called SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonin Noradrenaline Reuptake Inhibitors)
  • Tell your doctor or pharmacist before using MigraKind. Also see Other medicines and MigraKind, below. If you use MigraKind frequently. Using MigraKind too often may make your headaches worse.
  • Tell your doctor if this applies to you. He or she may recommend you stop using MigraKind. If you feel pain or tightness in your chest after you use MigraKind These effects may be intense but they usually pass quickly. If they don't pass quickly, or they become severe: Get medical help immediately. Section 4 (overleaf) has more information about these possible side effects. If three or more of the points above apply to you, you may be at higher risk of heart disease – see your doctor without taking MigraKind. If you are not sure, your pharmacist or doctor can help.
  • if your headaches usually last longer than 24 hours, or become more frequent
  • if you generally have four or more migraine attacks each month
  • if you do not recover completely in between your migraine attacks
  • if you are over 50 and this is your first headache of this type
  • if your migraine attacks get worse or become more frequent, or your symptoms change
  • if your migraine includes symptoms such as
  • weakness on one side of your body
  • clumsy and un-coordinated movements
  • reduced level of consciousness
  • a recent rash with a headache
  • double vision
  • tinnitus (ringing in the ears)
  • seizure (fit)- like movements The use of buprenorphine together with MigraKind can lead to serotonin syndrome, a potentially lifethreatening condition (see "Other medicines and MigraKind"). If any of the points in this list apply to you, and you haven't already talked to a pharmacist or doctor about these, get their advice before taking MigraKind. Other medicines and MigraKind Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes any herbal products or medicines you've bought without a prescription. Some medicines must not be taken with MigraKind and others may cause adverse effects if they are taken with MigraKind. You must tell your doctor if you are taking:
  • ergotamine also used to treat migraine, or similar medicines such as methysergide (see section 2 Don't use MigraKind).Don't use MigraKind at the same time as these medicines. Stop taking these medicines at least 24 hours before using MigraKind. Don't take any medicines which contain ergotamine or compounds similar to ergotamine again for at least 6 hours after using MigraKind.
  • other triptans/5-HT1 receptor agonists (such as naratriptan, rizatriptan, zolmitriptan), also used to treat migraine, (see section 2 Don't use MigraKind). Don't use MigraKind at the same time as these medicines. Stop taking these medicines at least 24 hours before using MigraKind. Don't take another triptan/5-HT1 receptor agonist again for at least 24 hours after using MigraKind.
  • MAOIs used to treat depression. Don't use MigraKind if you have taken these in the last 2 weeks.
  • SSRIs and SNRIs used to treat depression. Using MigraKind with these medicines can cause serotonin syndrome (a collection of symptoms which can include restlessness, confusion, sweating, hallucinations, increased reflexes, muscle spasms, shivering, increased heartbeat and shaking). Tell your doctor immediately if you are affected in this way.
  • St John's Wort (Hypericum perforatum). Taking herbal remedies that contain St John's Wort together with MigraKind may make side effects more likely.
  • Buprenorphine, naloxone: These medicines may interact with MigraKind and you may experience symptoms such as involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, hallucinations, coma, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature above 380C.Contact your doctor when experiencing such symptoms. Pregnancy, breast-feeding and fertility
  • If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. There is only limited information about the safety of this medicine for pregnant women, though up till now there is no evidence of any increased risk of birth defects. Your doctor will discuss with you whether or not you should use this medicine while you are pregnant
  • Don't breast-feed your baby for 12 hours after using this medicine. If you express any breast milk during this time, discard the milk and don't give it to your baby.
  • Some breastfeeding women report breast and/or nipple pain after use of sumatriptan. The pain is usually temporary and disappears in 3 to 12 hours. Driving and using machines Either the symptoms of migraine or your medicine may make you drowsy. If you are affected, do not drive or operate machinery. MigraKind contains lactose and sodium If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodiumfree'.

3.

How to take it

MigraKind

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Adults aged 18 to 65

  • Take one tablet as soon as possible at the first signs of a migraine headache.
  • If your symptoms start to come back, you can take a second tablet after 2 hours. You must leave at least 2 hours after the first tablet. Swallow each tablet whole with water. Don't take more than two tablets in 24 hours. Don't take more than two tablets for the same attack. If the first tablet does not provide any relief: Don't take a second tablet. If you use MigraKind too often, it may make your headaches worse. If this happens you should consult your doctor or pharmacist, who may tell you to stop taking MigraKind. You should wait at least 24 hours before taking a medicine containing a triptan (including other sumatriptan-containing products, zolmitriptan, rizatriptan, naratriptan) or at least 6 hours before taking a medicine containing ergotamine or methysergide. Talk to your doctor before you take any more MigraKind tablets. Getting no relief at all from MigraKind may mean that you do not have migraine. MigraKind is only to relieve migraine symptoms. Don't take it to try to prevent an attack. Don't take it until you are sure it's a migraine and not just a headache. What should I do if I take too many tablets? Taking too much could make you ill. Keep to the dose and follow the instructions. If you take too many tablets, tell a doctor straight away. Take the box and this leaflet with you. If you forget to take MigraKind Do not take a double dose to make up for a forgotten dose. Children under 18 and adults over 65 Do not take this medicine if you are under 18 or over 65 and have migraine symptoms. Talk to your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4.

Possible side effects

MigraKind can cause side effects, but not everybody gets them. Some symptoms may be caused by the migraine itself. Allergic reactions: get doctor's help straight away The following side effects have occurred but their exact frequency is not known. Some people may be allergic to these tablets. Signs of allergy include rash; hives (itchy rash); wheezing; breathlessness; swollen eyelids, face or lips; complete collapse. If you get any of these symptoms soon after taking MigraKind, don't take any more. Tell a doctor straight away. Take the packaging and this leaflet with you. Very rare side effects: tell doctor as soon as possible (affect less than 1 in 10,000 people)

Liver function changes. If you have a blood test to check your liver function tell your doctor or nurse that you are taking MigraKind.

Common side effects: tell doctor if long or severe (affect less than 1 in 10 people)

Pain, heaviness, pressure or tightness in the chest, throat or other parts of the body, or unusual sensations, including numbness, tingling and warmth or cold. These effects may be intense but generally pass quickly. If these effects continue or become severe (especially the chest pain):

  • Get medical help urgently. In a very small number of people these symptoms can be caused by a heart attack. Other common side effects include:
  • Feeling sick (nauseous) or being sick (vomiting) – although this is often part of the migraine attack itself.
  • Tiredness or drowsiness.
  • Dizziness, feeling weak, or getting hot flushes.
  • Feeling faint (blood pressure may go up or down).
  • Shortness of breath.
  • Temporary increase in blood pressure
  • Aching muscles
  • Short-lived/temporary muscle spasms of the jaw affecting jaw movement. Other rare side effects include (affect up to 1 in 1,000 people):
  • Breast pain

Some patients may get the following side effects but it is not known how often they occur:

  • Seizures/fits, tremors, muscle spasm, neck stiffness
  • Visual disturbances such as flickering, reduced vision, double vision, loss of vision, and in some cases even permanent defects (although these may be due to the migraine attack itself)
  • Heart problems, where your heartbeat may go faster, slower or change rhythm, chest pains (angina) or heart attack
  • Pale, blue-tinged skin and/or pain in your fingers, toes, ears, nose or jaw in response to cold or stress (Raynaudâ•TMs phenomenon)
  • Feeling faint (blood pressure may go down)
  • Pain in the lower left side of the stomach and bloody diarrhoea (ischaemic colitis)
  • Diarrhoea
  • If you had a recent injury or if you have inflammation (like rheumatism or inflammation of the colon) you may experience pain or pain worsening at the site of injury or inflammation.
  • Pain in the joints
  • Feeling anxious
  • Difficulty swallowing
  • Excessive sweating Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5.

How to store it

MigraKind

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister/carton after 'Exp (MM/YY)'. The expiry date refers to the last day of that month. Do not store above 25 ̊C. Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6.

More about MigraKind

What MigraKind tablet contains

  • The active substance is sumatriptan.

Each film coated tablet contains 50 mg sumatriptan (as the succinate). –

The other ingredients are: Core: lactose monohydrate, lactose, crosscarmellose sodium, microcrystalline cellulose, magnesium stearate. Coating: Lactose monohydrate, mannitol (E421), titanium dioxide (E171), triacetin and talc.

What MigraKind tablet looks like and contents of the pack Round white film coated tablets marked 'RDY' on one face and '292' on the other. Pack sizes: 2, 6 tablets Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer: Dr. Reddy's Laboratories (UK) Ltd, 410 Cambridge Science Park, Milton Road, Cambridge, CB4 0PE, United Kingdom Other formats of this leaflet A service is available to listen to or request a copy of this leaflet in Braille, large print or audio. please contact the marketing authorisation holder at the address above. This leaflet was last revised in August 2025.

Frequently asked questions about MigraKind 50 mg Film-Coated Tablets

How do I take MigraKind 50 mg Film-Coated Tablets?

MigraKind 50 mg Film-Coated Tablets comes as tablet containing 50mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in MigraKind 50 mg Film-Coated Tablets?

The active substance in MigraKind 50 mg Film-Coated Tablets is sumatriptan succinate.

Are there equivalent medicines to MigraKind 50 mg Film-Coated Tablets?

Medicines with the same active substance, strength and form include: Boots Migraine Relief 50 mg Tablets, Imigran 50mg Tablets, Imigran Radis 50mg Tablets. In total there are 6 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for MigraKind 50 mg Film-Coated Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get MigraKind 50 mg Film-Coated Tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Sumatriptan succinate (14 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

MigraKind film-coated tablets are indicated for the acute relief of migraine attacks, with or without aura. MigraKind film-coated tablets should only be used where there is a clear diagnosis of migraine.

4.2. Posology and method of administration

Posology

Adults (18-65 years of age)

MigraKind is indicated for the acute intermittent treatment of migraine. It should not be used prophylactically. The recommended dose of Sumibril/Migraitan should not be exceeded.

It is advisable that MigraKind be taken as early as possible after the onset of a migraine attack but it is equally effective at whatever stage of the attack it is administered.

The recommended dose of oral MigraKind is a 50mg tablet. Some patients may require 100mg.

If the patient has responded to the first dose but the symptoms recur, a second dose may be taken provided that there is a minimum interval of 2 hours between the two doses. Not more than two 50 mg tablets (total dose 100mg) may be taken in any 24 hour period or to treat the same attack.

Patients who do not respond to the prescribed dose of MigraKind should not take a second dose for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. MigraKind may be taken for subsequent attacks.

MigraKind is recommended as monotherapy for the acute treatment of migraine and should not be taken concomitantly with ergotamine or derivatives of ergotamine (including methysergide) (see section 4.3).

Paediatric population

The efficacy and safety of sumatriptan (film-coated) tablets/dispersible tablets in children aged less than 10 years have not been established. No clinical data are available in this age group.

The efficacy and safety of sumatriptan (film-coated) tablets/dispersible tablets in children 10 to 17 years of age have not been demonstrated in the clinical trials performed in this age group. Therefore the use of sumatriptan (filmcoated) tablets/dispersible tablets in children 10 to 17 years of age is not recommended (see section 5.1).

Elderly (Over 65 years of age)

Not to be used in those over 65 years of age.

Experience of the use of sumatriptan in patients aged over 65 years is limited.

The pharmacokinetics do not differ significantly from a younger population but until further clinical data are available, the use of MigraKind in patients aged over 65 years is not recommended.

Method of administration

Oral.

The tablets should be swallowed whole with water.

4.3. Contraindications

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

• Sumatriptan should not be given to patients who have had myocardial infarction or have ischaemic heart disease, coronary vasospasm (Prinzmetal's angina), peripheral vascular disease or patients who have symptoms or signs consistent with ischaemic heart disease.

• Sumatriptan should not be administered to patients with a history of cerebrovascular accident (stroke) or transient ischaemic attack (TIA).

• Sumatriptan should not be administered to patients with severe hepatic impairment

• The use of sumatriptan in patients with moderate and severe hypertension and mild uncontrolled hypertension is contraindicated

• Concurrent administration of monoamine oxidase inhibitors and sumatriptan is contraindicated.

• MigraKind must not be used within 2 weeks of discontinuation of therapy with MAOIs.

• The concomitant administration of ergotamine or derivatives of ergotamine (including methysergide) or any triptan/5-hydroxytryptamine1 (5-HT1) receptor agonist with sumatriptan is contraindicated (see section 4.5).

4.4. Special warnings and precautions for use

MigraKind should only be used where there is a clear diagnosis of migraine.

Sumatriptan is not indicated for use in the management of hemiplegic, basilar or ophthalmoplegic migraine.

Before treating with sumatriptan, care should be taken to exclude potentially serious neurological conditions (e.g. CVA, TIA) if the patient presents with atypical symptoms or if they have not received an appropriate diagnosis for sumatriptan use.

Following administration, sumatriptan can be associated with transient symptoms including chest pain and tightness which may be intense and involve the throat (see section 4.8). Where such symptoms are thought to indicate ischaemic heart disease, no further doses of sumatriptan should be given and appropriate evaluation should be carried out.

Sumatriptan should not be given to patients with risk factors for ischaemic heart disease, including those patients who are heavy smokers or users of nicotine substitution therapies, without prior cardiovascular evaluation (see section 4.3).

Special consideration should be given to postmenopausal women and males over 40 with these risk factors. These evaluations however, may not identify every patient who has cardiac disease and, in very rare cases, serious cardiac events have occurred in patients without underlying cardiovascular disease.

Sumatriptan should be administered with caution to patients with mild controlled hypertension, since transient increases in blood pressure and peripheral vascular resistance have been observed in a small proportion of patients (see section 4.3).

There have been rare post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. Serotonin syndrome has been reported following concomitant treatment with triptans and serotonin noradrenaline reuptake inhibitors (SNRIs).

If concomitant treatment with sumatriptan and an SSRI/SNRI is clinically warranted, appropriate observation of the patient is advised (see section 4.5).

Sumatriptan should be administered with caution to patients with conditions which may affect significantly the absorption, metabolism or excretion of drugs, e.g. impaired hepatic (Child Pugh grade A or B; see section 5.2) or renal function (see sect on 5.2). A 50mg dose should be considered in patients with hepatic impairment.

Sumatriptan should be used with caution in patients with a history of seizures or other risk factors which lower the seizure threshold, as seizures have been reported in association with sumatriptan (see section 4.8).

Patients with known hypersensitivity to sulphonamides may exhibit an allergic reaction following administration of sumatriptan. Reactions may range from cutaneous hypersensitivity to anaphylaxis. Evidence of cross-sensitivity is limited, however, caution should be exercised before using sumatriptan in these patients.

Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St John's Wort (Hypericum perforatum).

Prolonged use of any type of painkiller for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained and treatment should be discontinued. The diagnosis of Medication Overuse Headache (MOH) should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications.

Important information regarding the ingredients in this medicine

MigraKind contains Lactose

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

Studies in healthy subjects show that sumatriptan does not interact with propranolol, flunarizine, pizotifen or alcohol.

There are limited data on an interaction with preparations containing ergotamine or another triptan/5-HT1 receptor agonist. The increased risk of coronary vasospasm is a theoretical possibility and therefore concomitant administration is contraindicated (see section 4.3)

The period of time that should elapse between the use of sumatriptan and ergotamine-containing preparations or another triptan/5-HT1 receptor agonist is not known. This will also depend on the doses and types of products used. The effects may be additive. It is advised to wait at least 24 hours following the use of ergotamine-containing preparations or another triptan/5-HT1 receptor agonist before administering sumatriptan. Conversely, it is advised to wait at least 6 hours following use of sumatriptan before administering an ergotamine-containing product and at least 24 hours before administering another triptan/5-HT1 receptor agonist.

An interaction may occur between sumatriptan and monoamine oxidase inhibitors (MAOIs) and concomitant administration is contraindicated (see section 4.3).

There have been rare post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of SSRIs and sumatriptan. Serotonin syndrome has also been reported following concomitant treatment with triptans and SNRIs (see section 4.4).

4.6. Fertility, pregnancy and lactation

Pregnancy

Post-marketing data from the use of sumatriptan during the first trimester in over 1,000 women are available. Although these data contain insufficient information to draw definitive conclusions, they do not suggest an increased risk of congenital defects. Experience with the use of sumatriptan in the second and third trimester is limited.

Evaluation of experimental animal studies does not indicate direct teratogenic effects or harmful effects on peri- and postnatal development. However, embryo-foetal viability might be affected in the rabbit (see Section 5.3). Administration of sumatriptan should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.

Breast-feeding

Sumatriptan is excreted into breast milk, with average relative infant doses of < 4% following administration of a single dose of sumatriptan. Infant exposure can be minimised by avoiding breast feeding for 12 hours after treatment during which time any breast milk expressed should be discarded.

There have been reports of breast pain and/or nipple pain following sumatriptan use in breastfeeding women (see section 4.8). The pain was usually transient and disappeared in 3 to 12 hours.

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. Drowsiness may occur as a result of migraine or its treatment with sumatriptan. Caution is recommended when skilled tasks are to be performed e.g. driving or operating machinery

4.8. Undesirable effects

Adverse events are listed below by system organ class and frequency. Frequencies are defined as:

very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), not known (cannot be estimated from the available data). Some of the symptoms reported as undesirable effects may be associated symptoms of migraine.

Clinical Trial Data

Nervous System Disorders

Common:

Dizziness, drowsiness, sensory disturbance including paraesthesia and hypoaesthesia.

Vascular Disorders

Common:

Transient increases in blood pressure arising soon after treatment.

Flushing.

Respiratory, Thoracic and Mediastinal Disorders

Common:

Dyspnoea

Gastrointestinal Disorders

Common:

Nausea and vomiting occurred in some patients but it is unclear if this is related to sumatriptan or the underlying condition

Musculoskeletal and Connective Tissue Disorders

Common:

Sensations of heaviness (usually transient and may be intense and can affect any part of the body including the chest and throat).

Myalgia.

General Disorders and Administration Site Conditions

Common:

Pain, sensations of heat or cold, pressure or tightness ( these events are usually transient and may be intense and can affect any part of the body including the chest and throat: Feelings of weakness, fatigue (both events are mostly mild to moderate in intensity and transient).

Investigations

Very rare:

Minor disturbances in liver function tests have occasionally been observed.

Post-Marketing Data

Immune System Disorders

Not known:

Hypersensitivity reactions ranging from cutaneous hypersensitivity to anaphylaxis.

Nervous System Disorders

Not known:

Seizures, although some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures there are also reports in patients where no such predisposing factors are apparent.

Tremor, dystonia, nystagmus, scotoma

Eye Disorders

Not known:

Flickering, diplopia, reduced vision. Loss of vision including reports of permanent defects. However, visual disorders may also occur during a migraine attack itself.

Cardiac Disorders

Not known:

Bradycardia, tachycardia, palpitations, cardiac arrhythmias, transient ischaemic ECG changes, coronary artery vasospasm, angina, myocardial infarction (see sections 4.3 and 4.4).

Vascular Disorders

Not known:

Hypotension, Raynaud's phenomenon.

Gastrointestinal Disorders

Not known:

Ischaemic colitis, diarrhoea, dysphagia.

Musculoskeletal, Connective Tissue and Bone Disorders

Not known:

Neck stiffness.

Arthralgia.

Psychiatric disorders

Not known:

Anxiety.

Skin and subcutaneous tissue disorders

Not known:

Hyperhidrosis

Reproductive system and breast disorders

Rare:

Breast pain

General Disorders and Administration Site Conditions

Not known:

Pain trauma activated

Pain inflammation activated

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Doses in excess of 400 mg orally were not associated with side effects other than those mentioned in Section 4.8

Treatment

If overdose occurs, the patient should be monitored for at least 10 hours and standard supportive treatment applied as required.

It is unknown what effect haemodialysis or peritoneal dialysis has on the plasma concentrations of Sumatriptan.

💬 Ask about this leaflet

Ask anything about MigraKind 50 mg Film-Coated Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →